Improved clinical outcomes Evidence on venous mechanical thrombectomy followed by stenting

Similar documents
Improved clinical outcomes Evidence on venous thrombectomy followed by stenting

Techniques for thrombus removal in acute DVT Benefits of an Endovascular Approach for Rapid Flow Restoration in DVT

Successful recanalisation of venous thrombotic occlusions with Aspirex mechanical thrombectomy. Michael K. W. Lichtenberg

- Our patients with iliofemoral DVT - Effective thrombus removal with purely mechanical thrombectomy can lead to better outcomes

Aspirex for Upper and Lower Extremity DVT

Aggressive endovascular management of ilio-femoral DVT. thrombotic syndrome. is the key in preventing post

The evidence for venous interventions is evolving- many patients do actually benefit. Nils Kucher University Hospital Bern Switzerland

Chronic deep venous occlusions: Case planning, recanalization and stent technique

Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC

Should We Be More Aggressive in the Treatment of Acute DVT?

Venous interventions in DVT

Percutaneous Mechanical Thrombectomy for Acute Iliofemoral DVT with the Aspirex Catheter: The Dijon Experience

Clinical results of venous stents. Michael K. W. Lichtenberg MD, FESC

THERE IS NO ROLE FOR SURGICAL THERAPY FOR DVT

Technique de recanalisation: mon expérience avec Aspirex

Copy Here. The Easy One.. What is the Role of Thrombus Removal in Acute Proximal DVT after ATTRACT? Deep Venous Thrombosis Spectrum

Patency rates and clinical results of the Veniti VICI Stent for treatment of iliac vein lesion Data from the Arnsberg Venous Registry

Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome

Pharmaco-mechanical techniques stand alone procedures? Peter Neglén, MD, PhD SP Vascular Center Limassol Cyprus

REKANALISATION CHRONISCH VENÖSER VERSCHLÜSSE. Michael K. W. Lichtenberg, FESC

How to best approach chronic venous occlusions?

What Really Matters to Patient is QOL: Veniti Virtus Venous Feasibility Trial

Iliofemoral outflow obstruction. - Acute and chronic DVT - Michael K.W. Lichtenberg, MD. Venous Center Arnsberg

Ileo Femoral DVT Review and Update

Not all Leg DVT s are the Same: Which Patients Benefit from Interventional Therapy? Case 1:

PEARL REGISTRY Post Market Registry

Intervention for Deep Venous Thrombosis and Pulmonary Embolus

4/23/2009. September 15, 2008

Interventional Treatment VTE: Radiologic Approach

On Which Criteria Do You Select Your Stent for Ilio-femoral Venous Obstruction? North American Point of View

Venous stenting in Marseille

Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach

Optimal Utilization of Thrombolytics

Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis

Surgical approach for DVT. Division of Vascular Surgery Department of Surgery Seoul National University College of Medicine

VIRTUS: Trial Design and Primary Endpoint Results

PEARL Registry Update Overview Venous Arterial AV Access

Ultrasound-assisted catheter-directed thrombolysis: Does it really work? The BERNUTIFUL trial

Emerging Tools for Lytic-Free, Single-Session Treatment of Venous Thromboembolic Disease

Chronic Iliocaval Venous Occlusive Disease

Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON

Image-Guided Approach to Treatment of Patients with Nonthrombotic

Deep Venous Pathology. Eberhard Rabe Department of Dermatology University of Bonn Germany

What is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic

2017 Florida Vascular Society

Future Devices of Venous Interventions

Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial)

Complex Iliocaval Reconstruction PNEC. Seattle WA. Bill Marston MD Professor, Div of Vascular Surgery University of N.

The Evidence Base for Treating Acute DVT

VIVO-EU Results: Prospective European Study of the Zilver Vena TM Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction

Michael Meuse, M.D. Vascular and Interventional Radiology

Treatment of Chronic DVT with EKOS: Reproducing ACCESS PTS Data in Every Day Clinical Practice

The hallmark of percutaneous thrombus management

Understanding of the importance of venous

The hallmark of percutaneous thrombus management

Straub Endovascular System &

4/30/2018 CLOT+ In patients with an acute proximal deep vein thrombosis, pharmacomechanical catheter-directed thrombolysis does not reduce t

Mechanical treatment for acute DVT. Laurent Casbas, MD Toulouse, France

Re-intervention for occluded iliac vein stents

Meissner MH, Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, et al. J Vasc Surg. 2012;55:

A Dedicated Venous Self-expanding Oblique Hybrid Nitinol Stent (Sinus-Obliquus Stent)

VERNACULAR Trial & Clinical Experience with the VENOVO Venous Stent

The Conservative and Active Management of Post Thrombotic Syndrome

Evidence for endovascular therapy of iliofemoral DVT: CAVENT, ATTRACT, CAVA and more to come

Imaging, it s central role in planning and guiding intervention. Prof. Luis Izquierdo. MD, PhD, FEBVS

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Selection and work up for the right patients suspected of deep venous disease

VIRTUS Trial: Pivotal Cohort 12-Month Primary Safety and Efficacy Results of the VICI Venous Stent System

The Ideal Venous Stent and Early Results from Venous Stent Trials PNEC, Seattle

Complete Evaluation of the Chronic Venous Patient: Recognizing deep venous obstruction. Erin H. Murphy, MD Rane Center

Venous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.

J Jpn Coll Angiol, 2009, 49:

Chronic Venous Disease: A Complex Disorder. A N Nicolaides

Methods of Thrombus Fragmentation & Extraction. Methods of Thrombus Extraction

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Early clinical outcomes of a novel rheolytic directional thrombectomy technique for patients with iliofemoral deep vein thrombosis

5 year quality of life data after EKOS treatment in acute DVT

Acoustic Pulse Thrombolysis Treatment

Status of anticoagulation therapy in 2016: Is there a need for venous revascularization?

Catheter-directed thrombolysis of deep vein thrombosis: literature review and practice considerations

ENHANCING YOUR OPTIONS

Pulsar stent technology

BY DAVID GILLESPIE, MD; MARCIA JOHANSSON, RN, MS; AND CAROLYN GLASS, MD

Reducing Thrombotic Burden in Arterial Interventions. Mario Galli, MD Cardiovascular Interventional Unit S. Anna Hospital, Como, Italy

Venogram Versus Intravascular Ultrasound for Diagnosing and Treating Iliofemoral Vein Obstruction (VIDIO)

Mechanical Thrombectomy systems: The cost effective way to manage clot? Dr Stephen D SOUZA Dr Bella Huasen Interventional Radiology Royal Preston.

Percutaneously Inserted AngioVac Suction Thrombectomy for the Treatment of Filter-Related. Iliocaval Thrombosis

Patency and Clinical Outcomes of a Dedicated, Self-Expanding, Hybrid Oblique Stent Used in the Treatment of Common Iliac Vein Compression

Incidence and interventions for post-thrombotic syndrome

No financial disclosures

Safety and Feasibility of Ultrasound-accelerated Catheter-directed Thrombolysis in Deep Vein Thrombosis

EKOS. Interventional Vascular 3 February, Imagine where we can go.

DEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES

Starting with deep venous treatment

Post-thrombotic syndrome (PTS), often the

Deep Venous Intervention Techniques

Introduction. Keywords Haemorrhage, mechanical thrombolysis, post-thrombotic syndrome, vascular patency, venous thrombosis

Vessel preparation with scoring balloons prior to DCB or stenting

BC Vascular Day. Contents. November 3, Abdominal Aortic Aneurysm 2 3. Peripheral Arterial Disease 4 6. Deep Venous Thrombosis 7 8

Catheter direct thrombolysis: Role of actilyse in treatment of acute deep venous thrombosis

Transcription:

Improved clinical outcomes Evidence on venous mechanical thrombectomy followed by stenting Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany German Venous Centre Arnsberg, Germany

Disclosure Speaker name: Michael Lichtenberg I have the following potential conflicts of interest to report: X Consulting (CR Bard, Veniti, Volcano, Biotronik, Terumo, Boston, Straub Medical,Veryan, TVA medical, Spectranetics, Cook, Optimed) Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) X I do not have any potential conflict of interest

Venous disease Western Europe Venous Outflow Obstruction Country: Western Europe Population 18 Years Age 1 333.294.710 2016 Projection Acute Incidence 2 Annual Patients % Obstuctive Component Annual Treatable Patients DVT 0,25% 833.237 61% Chronic C6 Active Ulcers 0,1% 333.295 60,00% 199.977 *UK, DE, IT, ES, FR, NL CVD (C2-C6): 104.254.585 23.458.348 3 508.274 CEAP Classification Prevalence 4 Affected Population % Obstuctive Component Treatable Patients C0 No Disease 9,7% 32.396.246 N/A 0 C1 Reticular Veins 59,0% 196.643.879 N/A 0 C2 Varicose Veins 14,3% 47.627.814 22,00% 10.478.119 C3 Edema 13,4% 44.694.821 21,80% 6 9.743.471 C4 Skin Pigmentation 2,9% 9.532.229 21,80% 6 2.078.026 C5 Healed Ulcers 0,6% 2.066.427 21,80% 6 450.481 5 7 1. Wikipedia, 2016: Western Europe [https://en.wikipedia.org/wiki/western_europe] 2. Coon WW, Willis III PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh Community Health. Circulation. 1973;48:839-846. 3. Oguzkurt L, Ozkan U, Ulusan S, Koc Z, Tercan F. Compression of the left common iliac vein in asymptomatic subjects and patients with left iliofemoral deep vein thrombosis. J Vasc Interv Radiol. 2008;19:366-371. 4. Maurins U, Hoffmann BH, Lösch C, Jöckel K-H, Rabe E, Pannier F. Distribution and prevalence of reflux in the superficial and deep venous system in the general population - results from the Bonn Vein Study, Germany. J Vasc Surg. 2008;48:680-87. 5. Ananikian PP, Nanian AM, Galstian SM, Pogoisan BS. Clinical aspects, diagnosis and treatment of varicose veins of the lower limbs associated with extravasal compression of the external iliac vein. Kardiologiia. 1984 Feb;24(2):97-100. 6. Raju S, Neglén P. High prevalence of nonthrombotic iliac vein lesions in chronic venous disease: A permissive role in pathogenicity. J Vasc Surg. 2006;44:136-44. 7. Marston W, Fish D, Unger J, Keagy B. Incidence of and risk factors for iliocaval venous obstruction in patients with active or healed venous leg ulcers. J Vasc Surg. 2011;53:1303-1308.

Venous outflow obstruction webs, spurs, chords

Konservative Therapie

KAHN et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. Journal of Thrombosis and Haemostasis 2009, 6: 1105 1112

Catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of proximal deep vein thrombosis - a meta-analysis Vasa 2015 May;44(3):195-202

Iliofemorale Offenheitsrate nach 6 Monaten Persistierende venöse Obstruktion Im FU Vasa 2015 May;44(3):195-202

Indication for proximal venous thrombectomy 23 y female patient 65 y male patient 80 y female patient CDT with high risk CDT with high risk Young and active patient Descending ileofemoral thrombosis May-Thurner Syndrome Phlegmasia, descending IVC thrombosis Bowel cancer Stenosis of right iliac vein With thrombus Lymphocele compression

EKOS Peripheral Infusion System Early Clot Removal Many Choices Trellis System AngioJet Aspirex (Rotational thrombectomy) Indigo System (Penumbra) 6 10 French M. Lichtenberg (Hrsg.), C. Tiefenbacher, M. Katoh, P. Minko, E. Minar, C. Wissgott, A. Storck, B. Hailer: Thrombektomie: medikamentös, mechnisch, operativ. Uni-med Verlag, 2013

21 y, female, descending DVT in May Thurner syndrome. Transpopliteal access, 10 F Aspirex 8 F: blood volume aspiration up to 75 ml/min 10 F: blood volume aspiration up to 130 ml/min

6 10 French Veniti Vici

Standard Treatment vs. CDT Enden T, et al: CaVenT Study Follow-Up 24 months: Number needed to treat: 7 Lancet. 2012 Jan 7;379(9810):31-8.

Long-Term Results using Catheter-directed Thrombolysis in 103 Lower Limbs with Acute Iliofemoral Venous Thrombosis N. Bækgaard, R. Broholm, S. Just, M. Jørgensen, L.P. Jensen European Journal of Vascular and Endovascular Surgery, Volume 39, Issue 1, Pages 112-117 (January 2010) All patients with patent veins and normal valve function showed no sign of dermal pigmentation, ulceration or venous claudication at follow-up 1 major bleeding complication

PEARL Comparison Treatment of Lower Extremity DVT PEARL * Venous CaVenT Registry CDT Standard # of Patients 329 287 90 99 # of Sites 32 63 20 Prior DVT 40% 31% 10% 9% Primary Treatment AngioJet Thrombectomy With or Without PMT CDT CDT LMWH Stent Placement 35% 33% 17% NA Primary access Popliteal Popliteal Popliteal NA Male 57% 48% 64% 62% Age (mean) 52.2 yrs 47.5 yrs 53.3 yrs 50.0 yrs Treatment Location Iliofemoral femoral pop Iliofemoral femoral pop CFV or iliofemoral Limbs Involved Left=62%; Right=38% *Garcia,MJ, et al. J Vasc Interv Radiol 2015; 26:777-785 Mewissen MW, Seabrook GR. Radiology 1999:211:39-49 Enden, Haig Y. Lancet 2012:379:31-38 Left=61%; Right=39% Left=60%; Right=40% Left=62%; Right=38% CDT, catheter-directed thrombolysis; CFV, common femoral vein; LMWH, low molecular weight heparin; PMT, pharmacomechanical thrombolysis

PEARL Comparison Treatment of Lower Extremity DVT Overall % Thrombus Removal By Lytic Groups: % thrombus removal CDT (N=28) CDT+PPS/ RL (N=167) PPS/RL (N=113) Acute: % Thrombus Removal Chronic: % Thrombus Removal Primary Patency Freedom from Rethrombosis PEARL* Venous CaVenT Registry CDT Standard 96% 83% 89% NA 93% NA NA 97% NA NA 95% NA NA 97% 86% 89% 95% 68% NA NA 6 Mon= 87%; 12 Mon=83% 6 Mon=65%; 12 Mon=60% 6 Mon = 65.9% 6 Mon = 47.4% NA NA NA *Garcia,MJ, et al. J Vasc Interv Radiol 2015; 26:777-785 Mewissen MW, Seabrook GR. Radiology 1999:211:39-49 Enden, Haig Y. Lancet 2012:379:31-38

2. Indications for early thrombus removal 2.1. We suggest a strategy of early thrombus removal in selected patients meeting the following criteria: (a) a first episode of acute iliofemoral deep venous thrombosis (b) symptoms <14 days in duration (c) a low risk of bleeding (d) ambulatory with good functional capacity and an acceptable life expectancy (Grade 2C)

Two center retrospective data analysis for DVT thrombectomy with the Aspirex catheter Dr. Thomas Heller Dr. Michael Lichtenberg 43 Aspirex thrombectomy procedures for iliofemoral DVT Technical success analysis Safety analysis

Ileofemoral DVT therapy with Aspirex catheter May-Thurner syndrom: 43.1 years, 66 % female Cancer patients with more phlegmasia symptoms Duration of symptoms: 1 day 3 months Hemodynamic technical success in cath lab with Aspirex and stent implantation: 97 % (42/43 patients) No prolonged lytic therapy Stent rate 100 % in Arnsberg patients / 95 % Rostock IVUS 100 % Stent rate 1,25 / patient Complications: No bleeding, PE

The difference in PTS severity was almost entirely seen in the iliofemoral DVT patients with moderate/severe PTS seen in 18.4% of PCDT patients versus 28.2% in the no-pcdt group Overall, the 2-year data supported the use of standard therapy/anticoagulation alone in most DVT patients PCDT was not shown to prevent postthrombotic syndrome (PTS) and was associated with increased bleeding. Leg pain and leg swelling were significantly improved in patients who received PCDT vs no-pcdt: (leg pain, 10 days: -1.62 vs -1.29; P =.019; 30 days: -2.17 vs -1.83; P =.026) (leg swelling, 10 days: -0.26 vs +0.27; P =.024; 30 days: - 0.74 vs -0.28; P =.051). However, PCDT was shown to reduce early DVT symptoms as well as PTS severity The PCDT arm saw a statistically significant higher rate of major bleeding within 10 days (1.7% vs 0.3%; P =.049),

Conclusion DVT thrombectomy Is effective in venous thrombus removal Even in more organized thrombus Restores vein patency in upper and lower limb Has low risk and less side effects with PMT No ICU stay End it in the Angiolab PMT will be the standard treatment Treat the underlying reason with a dedicated iliac vein stent

THANK YOU FOR YOUR ATTENTION

Improved clinical outcomes Evidence on venous mechanical thrombectomy followed by stenting Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany German Venous Centre Arnsberg, Germany